Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference
Cocrystal Pharma (Nasdaq: COCP), a clinical-stage biotechnology company, announced it will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference from March 15-17, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cocrystal Pharma (Nasdaq: COCP), a clinical-stage biotechnology company, announced it will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference from March 15-17, 2021. The company specializes in developing antiviral therapeutics targeting various viruses, including SARS-CoV-2 and hepatitis C. A pre-recorded webcast of Cocrystal's presentation is available on their website. Interested investors can arrange virtual meetings through Roth Capital Partners or LHA Investor Relations.
Details
News Market Reaction – COCP
The recorded move for COCP in the trading session of this news was +10.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021. A webcast of Cocrystal’s presentation has been pre-recorded and is available on the Company’s website here.
Investors interested in arranging a virtual meeting with Cocrystal management should contact their Roth Capital Partners sales representative or LHA Investor Relations. Roth Conference information is available here.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.